Authentication of paper assessment orders upheld, while qualifying repairs, consumables and vendor advance write-offs remain deductible business claim...
Transaction value cannot be rejected solely on non-statutory valuation guidelines without corroborative evidence supporting reassessment of final cust...
Cross-examination rights and corroborated evidence limit customs penalties for misdeclaration in genuine import transactions involving documented clea...
Tariff classification of vehicle gear components follows the specific gearing entry, displacing motor-vehicle parts classification and related liabili...
Necessary-party requirements limit impleadment of independent entities, while deferred consideration does not create an appealable adverse determinati...
Commission payments to agents were allowable as business...
Commission expenditure linked to pharmaceutical marketing income qualifies as business deduction when recipient identity, genuineness and business purpose are established.
Contents
Summary
Note
Bookmark
Share
✓ Copied successfully !
Print
Print Options
For full text, please login
Login to TaxTMI
Verification Pending
The Email Id has not been verified. Click on the link we have sent on
Commission payments to agents were allowable as business expenditure where they were intrinsically linked to commission income earned from pharmaceutical companies for facilitating marketing and sales. The disallowance based on an assumption that payments related to direct sales to Government hospitals lacked factual support. Recipient details, tax deduction at source, banking-channel payments and recipients' income-tax returns established the identity of recipients, genuineness of payments and business purpose. With no evidence of fictitious payments, non-existent recipients or diversion back to the assessee, the expenditure satisfied the wholly and exclusively business-purpose test and the disallowance was deleted.
Commission payments to agents were allowable as business expenditure where they were intrinsically linked to commission income earned from pharmaceutical companies for facilitating marketing and sales. The disallowance based on an assumption that payments related to direct sales to Government hospitals lacked factual support. Recipient details, tax deduction at source, banking-channel payments and recipients' income-tax returns established the identity of recipients, genuineness of payments and business purpose. With no evidence of fictitious payments, non-existent recipients or diversion back to the assessee, the expenditure satisfied the wholly and exclusively business-purpose test and the disallowance was deleted.
Note: It is a system-generated summary and is for quick reference only.
TaxTMI 
of 4803
Join Channel
TaxTMI 
